Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

telatinib

National Institutes of Health

Related topics

Related topics

4 relations

Broader (2)

PyridazinesPyridines
Receptor Tyrosine Kinase InhibitionTelatinib Mesylate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Telatinib Is an Effective Targeted Therapy for Pseudomyogenic Hemangioendothelioma
Purpose: Pseudomyogenic hemangioendothelioma (PHE) is an extremely rare locally aggressive neoplasm with endothelial… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Review
2017
Review
2017
Anti-angiogenic Therapy in Patients with Advanced Gastric and Gastroesophageal Junction Cancer: A Systematic Review
Despite advancements in therapy for advanced gastric and gastroesophageal junction cancers, their prognosis remains dismal. Tumor… Expand
  • figure 1
2014
2014
Telatinib reverses chemotherapeutic multidrug resistance mediated by ABCG2 efflux transporter in vitro and in vivo.
Multidrug resistance (MDR) is a phenomenon where cancer cells become simultaneously resistant to anticancer drugs with different… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Review
2014
Review
2014
Repositioning of Tyrosine Kinase Inhibitors as Antagonists of ATP-Binding Cassette Transporters in Anticancer Drug Resistance
The phenomenon of multidrug resistance (MDR) has attenuated the efficacy of anticancer drugs and the possibility of successful… Expand
  • figure 1
  • figure 2
  • figure 3
2011
2011
Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors.
BACKGROUND Blocking both receptor and ligand of the vascular endothelial growth factor (receptor) VEGF(R) pathway might be… Expand
2010
2010
Phase I Evaluation of Telatinib, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Combination with Irinotecan and Capecitabine in Patients with Advanced Solid Tumors
Purpose: We studied the safety and tolerability of telatinib, an orally available, small-molecule tyrosine kinase inhibitor of… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
2009
2009
Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients…
PURPOSE Telatinib (BAY 57-9352) is an orally available tyrosine kinase inhibitor of vascular endothelial growth factor receptor… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • table 4
2009
2009
Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors
SummaryPurpose Telatinib is an orally active small-molecule tyrosine kinase inhibitor of kinase insert domain receptor (KDR… Expand
  • table 1
  • table 2
  • table 3
  • table 4
Highly Cited
2008
Highly Cited
2008
Hypertension and Rarefaction during Treatment with Telatinib, a Small Molecule Angiogenesis Inhibitor
Purpose: Hypertension is a commonly reported side effect in antiangiogenic therapy. We investigated the hypothesis that telatinib… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
2008
2008
Phase I dose escalation study of telatinib (BAY 57-9352) in patients with advanced solid tumours
Telatinib (BAY 57-9352) is an orally available, small-molecule inhibitor of vascular endothelial growth factor receptors 2 and 3… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE